… and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the
… by immunostaining does not reliably predict clinical outcome of EGFR-targeted treatment has …

BACKGROUND Prostate tumors express high levels of transforming growth factor‐β1 (TGF‐β1)
and seem to acquire resistance to its antiproliferative effects with tumor progression. …

… Epidermal growth factor receptor (EGFR) expression is associated with … Clinical and biological
features of EGFR‐positive and EGFR‐negative tumors were compared. Clinical outcomes …

… Moreover, when looking for a potential biological concentration response effect between
VEGF expression levels and clinical outcome, we were able to demonstrate that absolute levels …

… growth factor 23 (FGF23) is a key phosphate-regulating hormone that has been associated
with adverse outcomes in … and outcomes in patients with type 2 diabetes with or without CKD. …

… Clinical outcomes were analyzed to look for differences based on EGFR and KRAS genotypes,
as well as clinical … receptor (EGFR) and KRAS mutations on clinical outcomes to EGFR–…

… Despite the many clinical trials conducted so far, data have shown disappointing outcomes.
The efforts done to improve outcomes, efficacy, and safety in the identification of targets in …

… that showed significant differences in biological properties and clinical outcome (Fig. 5). Thus…
a positive hepatocyte growth factor/c-Met signature and the worst patient outcome. Here we …

… and expression ratio showed similar correlation with clinical outcome. … clinical outcome.
EIA can give an assessment with less sampling bias, and can measure various growth factors …

… on clinical trial data alone. We aimed to describe clinicopathological features, patterns of
recurrence and clinical outcomes of HER2-positive breast cancer according to HR status. …